Discovery of Quinazoline and Quinoline-Based Small Molecules as Utrophin Upregulators via AhR Antagonism for the Treatment of Duchenne Muscular Dystrophy
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c00398 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Surojit Ghosh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Smart Healthcare Department, Interdisciplinary Research Platform, Indian Institute of Technology, Jodhpur, Rajasthan 342030, India. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Utrophin, Quinolines, Receptors, Aryl Hydrocarbon. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Science and Engineering Research Board, Indian Institute of Technology Jodhpur, Ministry of Education, India.
Abstract (Originalsprache)
Duchenne muscular dystrophy (DMD) is a fatal muscle-wasting disease caused by the absence of a dystrophin protein. Elevating utrophin, a dystrophin paralogue, offers an alternative therapeutic strategy for treating DMD, irrespective of the mutation type. Herein, we report the design and synthesis of novel quinazoline and quinoline-based small molecules as potent utrophin modulators screened via high throughput In-Cell ELISA in C2C12 cells. Remarkably, lead molecule SG-02, identified from a library of 70 molecules, upregulates utrophin 2.7-fold at 800 nM in a dose-dependent manner, marking the highest upregulation within the nanomolar range. SG-02's efficacy was further validated through DMD patient-derived cells, demonstrating a significant 2.3-fold utrophin expression. Mechanistically, SG-02 functions as an AhR antagonist, with excellent binding affinity (Kd = 41.68 nM). SG-02 also enhances myogenesis, as indicated by an increased MyHC expression. ADME evaluation supports SG-02's oral bioavailability. Overall, SG-02 holds promise for addressing the global DMD population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Smart Healthcare Department, Interdisciplinary Research Platform, Indian Institute of Technology, Jodhpur, Rajasthan 342030, India.
- Department of Bioscience and Bioengineering, Indian Institute of Technology, Jodhpur, Rajasthan 342030, India.
- Inserm, Institut de Myologie, Centre de Recherche en Myologie,Sorbonne Université, F-75013 Paris, France.
- Department of Chemistry, Indian Institute of Technology, Jodhpur, Rajasthan 342030, India.
ORCID-Profile: Nirmal Kumar Rana, Surajit Ghosh
Förderung
- Science and Engineering Research Board
- Indian Institute of Technology Jodhpur
- Ministry of Education, India
Zitieren
APA
Ghosh, S., Arshi, M. U., Ghosh, S., Jash, M., Sen, S., Mamchaoui, K., Bhattacharyya, S., Rana, N. K., & Ghosh, S. (2024). Discovery of Quinazoline and Quinoline-Based Small Molecules as Utrophin Upregulators via AhR Antagonism for the Treatment of Duchenne Muscular Dystrophy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00398
Vancouver
Ghosh S, Arshi MU, Ghosh S, Jash M, Sen S, Mamchaoui K, et al. Discovery of Quinazoline and Quinoline-Based Small Molecules as Utrophin Upregulators via AhR Antagonism for the Treatment of Duchenne Muscular Dystrophy. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00398
BibTeX
@article{Ghosh2024,
author = {Ghosh, Surojit and Arshi, Mohammad Umar and Ghosh, Satyajit and Jash, Moumita and Sen, Samya and Mamchaoui, Kamel and Bhattacharyya, Sudipta and Rana, Nirmal Kumar and Ghosh, Surajit},
title = {Discovery of Quinazoline and Quinoline-Based Small Molecules as Utrophin Upregulators via AhR Antagonism for the Treatment of Duchenne Muscular Dystrophy},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c00398}
}
EUVIMED